Qi RB, Wu ZH. Advanced lung adenocarcinoma with EGFR 19-del mutation transforms into squamous cell carcinoma after EGFR tyrosine kinase inhibitor treatment. World J Clin Cases 2024; 12(32): 6543-6546 [PMID: 39554895 DOI: 10.12998/wjcc.v12.i32.6543]
Corresponding Author of This Article
Zheng-Hao Wu, MD, Doctor, Research Associate, Surgeon, Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, Hubei, China.421910799@qq.com
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 16, 2024; 12(32): 6543-6546 Published online Nov 16, 2024. doi: 10.12998/wjcc.v12.i32.6543
Advanced lung adenocarcinoma with EGFR 19-del mutation transforms into squamous cell carcinoma after EGFR tyrosine kinase inhibitor treatment
Ruo-Bing Qi, Zheng-Hao Wu
Ruo-Bing Qi, Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Zheng-Hao Wu, Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China
Author contributions: Qi RB designed the research study, analyzed the data, and wrote the manuscript; Wu ZH performed the research; Qi RB and Wu ZH contributed new reagents and analytic tools; all authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zheng-Hao Wu, MD, Doctor, Research Associate, Surgeon, Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, Hubei, China.421910799@qq.com
Received: June 19, 2024 Revised: August 2, 2024 Accepted: August 13, 2024 Published online: November 16, 2024 Processing time: 96 Days and 12.5 Hours
Abstract
In this editorial we comment on the article by Ji et al. We focus specifically on the EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment and the development of drug resistance to EGFR-TKIs.
Core Tip: Patients treated with EGFR tyrosine kinase inhibitors (EGFR-TKIs) will inevitably face resistance issues, and resistance to EGFR-TKIs can be divided into two categories: Primary and acquired. Pathological transformation is one of the mechanisms for acquired resistance to EGFR-TKIs, with the transformation to squamous cell carcinoma being relatively rare. This case report provides detailed information on a 67-year-old female patient with advanced lung adenocarcinoma and an EGFR 19del mutation who developed resistance after treatment with EGFR-TKIs.
